Protagonist Therapeutics Announces U.S. FDA Approval of Hepcidin Mimetic Peptide MIMRYLO(TM) (rusfertide) for Polycythemia Vera
RegulatoryapprovedMIMRYLOPositive
AI Analysis
Summary
Protagonist Therapeutics announced U.S. FDA approval of MIMRYLO (rusfertide), a hepcidin mimetic peptide, for the treatment of polycythemia vera.
Outcome Details
U.S. FDA approval of hepcidin mimetic peptide for polycythemia vera
Importance:9/10
Sentiment:
0.95
FDA_approvalhepcidin_mimeticpolycythemia_verarare_disease
Related Companies
Read the original article
Published by yahoo_finance on August 29, 2026 12:30 AM